Phase 1b Study of IDH Inhibition With Enasidenib and MEK Inhibition With Cobimetinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations
Latest Information Update: 09 Jun 2025
At a glance
- Drugs Cobimetinib (Primary) ; Enasidenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 03 Jun 2025 Planned End Date changed from 2 May 2025 to 3 May 2027.
- 03 Jun 2025 Planned primary completion date changed from 2 May 2025 to 3 May 2027.
- 03 Jun 2025 Status changed from recruiting to suspended.